Supporting Information

Early and late steps of quinine biosynthesis
Francesco Trenti, Kotaro Yamamoto, Benke Hong, Christian Paetz, Yoko Nakamura, Sarah E. O’Connor

Department of Natural Product Biosynthesis, Max Planck Institute for Chemical Ecology, Hans-Knöll-Straße 8, 07745 Jena, Germany

Contents

Chemicals and molecular biology kits............................................................................................................2
RNA purification and sequencing......................................................................................................................2
Mass spectrometers parameters......................................................................................................................3
Untargeted UPLC/MS analysis.........................................................................................................................3
Targeted UPLC/MS analysis............................................................................................................................3
C. pubescens metabolite analysis.....................................................................................................................3
Candidate gene cloning.......................................................................................................................................3
Protein expression and purification..................................................................................................................4
E. coli soluBL21 expression and purification...................................................................................................4
S. cerevisiae expression and microsome preparation.........................................................................................4
Enzymatic assays.................................................................................................................................................5
MDH and esterase assays....................................................................................................................................5
Cytochrome P450 assays....................................................................................................................................5
Yeast feeding assays............................................................................................................................................5
In vitro microsome assays..................................................................................................................................5
OMT enzyme assays..........................................................................................................................................5
CpOMT1 conversion rate....................................................................................................................................5
Dihydrocorynantheal purification.....................................................................................................................6
NMR analysis.......................................................................................................................................................6
Synthesis of Quinine Analogs.............................................................................................................................7
Cinchoninone 16 and Cinchonidone 17................................................................................................................7
6’-Hydroxycinchonidone 25................................................................................................................................7
6’-Hydroxycinchonone 24..................................................................................................................................8
6’-Methoxycinchonidone 26 and 6’-Methoxycinchoninone 23...........................................................................8
6’-Hydroxycinchoninone 4...................................................................................................................................8
Supplementary Figures and Tables.....................................................................................................................10
References..........................................................................................................................................................32
**Materials**

**Chemicals and molecular biology kits**

All solvents used for extractions, chemical synthesis and preparative HPLC were of HPLC grade, whilst solvents for UPLC/MS analysis were of MS grade. All solvents were purchased from Fisher Scientific. Quinine 1, quinidine 5, cinchonine 6 and cinchonidine 7 standards were purchased from Sigma-Aldrich. Notably all these compounds come with a contamination of their respective dehydro-forms as reported in their description sheet provided by Sigma-Aldrich. Strictosidine 12 was prepared as previously described. Synthesis of cinchona alkaloids that are not commercially available is described below.

RNA extraction reagents, CTAB (Hexadecyltrimethylammonium bromide); PVP40 (Polyvinylpyrrolidone); Chloroform – isoamyl alcohol mixture (24:1); β-Mercaptoethanol; Lithium chloride (LiCl); spermidine trihydrochloride; SDS (Sodium dodecyl sulfate); diethylypyrocarbonate; and RNaseZap were purchased from Sigma-Aldrich. Ethanol absolute; EDTA pH 8; NaCl; Ultra Pure Tris-HCl buffer 1 M pH 8.0; and water sterile for RNA work were purchased from Fisher Scientific. Carbenicillin was purchased from Formedium.

All gene and fragment amplifications were performed using Platinum SuperFi polymerase (Thermo Fisher) whilst colony PCR reactions were performed using Phire II master mix (Thermo Fisher). All primers were purchased from Sigma-Aldrich. PCR product purifications were performed using the Zymo Research PCR clean-up kit. Plasmids purifications were performed using Promega Wizard minipreps. cDNA was prepared using Transcriptor reverse transcriptase (Roche) whilst colony PCR product purifications were performed using Promega Wizard minipreps. cDNA was prepared using Superscript IV VILO master mix and Turbo DNase (Thermo Fisher). All restriction enzymes were purchased from NEB.

**Methods**

**RNA purification and sequencing**

Plant material was harvested from roots and stems, as well as from young leaves. Total RNA was extracted using the CTAB protocol, which is an optimized procedure for extracting total RNA from tissues containing elevated levels of polysaccharides and polyphenolics compounds. All surfaces, gloves and equipment were cleaned by wiping with RNaseZap. Extraction buffer EB (CTAB 2% w/v; PVP40 2% w/v; Tris-HCl pH 8.0 100 mM; EDTA pH 8.0 25 mM; NaCl 2 M) (10 mL) was heated to 65 ºC and then 200 µL of β-mercaptoethanol and 0.05% spermidine trihydrochloride were added. Frozen ground tissue (100 mg) was extracted with 800 µL of warm EB and vortexed. Samples were incubated at 65 ºC for 10 minutes and vortexed 8 times vigorously during the incubation. Cooling at room temperature for 2 minutes followed. A solution of 24:1 chloroform:isoamyl alcohol (600 µL) was added and samples vortexed vigorously for 2 minutes. Samples were centrifuged at room temperature 12,000 g for 20 minutes, at which point the phases were clearly separated. The supernatant (~550 µL of viscous aqueous phase) was carefully transferred to a new 1.5 mL tube, and was re-extracted with ~550 µL of 24:1 chloroform:isoamyl alcohol solution and vortexed for 1 minute. Centrifugation and supernatant collection ensued. To precipitate nucleic acids, 0.25 volumes (~135 µL) of LiCl 10 M was added to the combined viscous aqueous phases. Samples were mixed by inverting the tubes and incubated overnight at 4 ºC. The next day, RNA was pelleted by centrifuging the samples at 14,000 g for 40 minutes at 4 ºC. The supernatant was carefully discarded using a pipette. The pellets were resuspended in 500 µL SSTE buffer (NaCl 1 M; SDS 0.5%; Tris-HCl pH 8.0 10 mM; EDTA pH 8.0 1 mM) and vortexed for ~10 seconds. The samples were extracted with equal volume (500 µL) of 24:1 chloroform:isoamyl alcohol and vortexed. Centrifugation at 14,000 g for 30 minutes at 4 ºC followed until phase separation. The viscous aqueous phase (~500 µL) was carefully recovered to a fresh 1.5 mL tube. Ice-cold absolute ethanol (100%) (2 volumes, ~1000 µL) was added and mixed well by vortexing for 10 seconds. RNA was precipitated at -80 ºC for 90 minutes. After incubation, samples were centrifuged at 14,000 g for 30 minutes at 4 ºC, and the supernatant was completely removed. The pellets were washed with 1 mL of 75% ice cold ethanol and mixed well by vortexing for 10 seconds. The samples were centrifuged at 14,000 g for 30 minutes at 4 ºC, and supernatant was discarded. The pellets were completely dried at room temperature for ~30 minutes under sterile clean bench. The pellet containing total RNA was dissolved in 30 µL of water (0.1% diethylypyrocarbonate; DNase, RNase free). Quantification and quality control were performed spectrophotometrically by analyzing absorption ratios: A260/A280 and A260/A230. Absorbance ratios detect polysaccharide/polyphenolic contaminants and protein contaminates respectively. Typical absorbance ratio for good quality RNA are A260/A280 ~1.9 and A260/A230 ~2.1. Samples were stored at -80 ºC.
Each sample was prepared in 5 biological replicates (Cp1-5). Samples with RNA concentration ranging from 100-500 ng/µL and acceptable quality (A$_{260}$/A$_{280}$ and A$_{260}$/A$_{320} \sim 2$) were sent to BGI-seq for sequencing, assembly and annotation.

**Mass spectrometers parameters**

**Untargeted UPLC/MS analysis**

Samples were analyzed using Bruker Impact II high resolution Quadrupole Time-Of-Flight mass spectrometer (Q-TOF) coupled with ELUTE LC system.

**Method 1**

Ionization was performed via pneumatic-assisted electrospray ionization in positive mode (ESI+) with a capillary voltage of 4500 V and an end plate offset of 500 V; a nebulizer pressure of 2.5 bar was used, with nitrogen at 250°C and a flow of 11 L/min as the drying gas. Acquisition was done at 12 Hz following a mass range from 20 to 1000 m/z, with data-dependent MS/MS and an active exclusion window of 0.2 min, a reconsideration threshold of 1.8-fold change. Fragmentation was triggered on an absolute threshold of 400 and acquired on the most intense peaks using a target intensity of 20000 counts, with MS/MS spectra acquisition between 12 and 20 Hz, and limited to a total cycle time range of 0.5 s. Collision energy was determined automatically by the software depending on m/z value. At the beginning of each run, an injection of a sodium formate-isopropanol solution was performed and the m/z values were re-calibrated using the expected cluster ion m/z values. Samples were run in at a flowrate of 0.6 mL/min in a formic acid 0.1% - acetonitrile (plus 0.1% formic acid) gradient linearly increasing from 5% to 20% acetonitrile in 15 minute using analytical Phenomenex Kinetex column (2.6 µm; XB-C18; 100 Å; column temperature 40°C). 2 µL of samples were injected.

**Method 2**

As Method 1, with exception of capillary voltage set at 3500 V and mass range from 800 to 1000 m/z. Samples were run in at a flowrate of 0.6 mL/min in a formic acid 0.1% - acetonitrile (plus 0.1% formic acid) gradient linearly increasing from 10% to 30% acetonitrile in 6 minutes using analytical Phenomenex Kinetex column (2.6 µm; XB-C18; 100 Å; column temperature 40°C). 2 µL of samples were injected.

**Targeted UPLC/MS analysis**

Bruker EVOQ Elite triple quadrupole MS system coupled with ELUTE LC system was used in multiple reaction monitoring (MRM) mode. Ionization was performed via heated electrospray ionization (HESI) in positive mode with a capillary voltage of 3500 V; cone temperature of 350 °C; cone gas flow set at 20; heated probe temperature of 450 °C; nebulizer gas flow set at 50; and probe gas flow set at 45. The source conditions were optimized using authentic standards of quinine 1, 6'-methoxychinoninone 23, 6'-hydroxychinonidone 25, and 6'-hydroxychinonidone 4. Compounds with ions quantifiers’ and qualifiers’ collision energies are listed in Table S1. Note that for every sample, the doubly charged m/z values were used as parental ions. Samples were run in a gradient 0.1% formic acid-acetonitrile (0.1% formic acid) in a two-step gradient of 5 minutes total and 0.6 mL/min: (first step) linear gradient 10%-17% acetonitrile for 3 minutes and (second step) linear gradient 17%-40% acetonitrile for 2 minutes using analytical Phenomenex Kinetex column (2.6 µm; XB-C18; 100 Å; column temperature 40°C). 2 µL of samples were injected.

**C. pubescens** metabolites analysis

The same plant material used for RNA analysis was also subjected to metabolonoma analysis. Plant material was snap-frozen with liquid nitrogen, ground with mortar and pestle and extracted with MeOH. The volume of MeOH was normalized on fresh tissue weight (100:1 = mg:mL). Plant material was centrifuged at 16000 g for 10 minutes and the supernatant filtered with Fisher polytetrafluoroethylene (PTFE) syringe filters (0.2 µm). The resulting methanolic extracts were diluted 1:10 in methanol and analyzed by untargeted UPLC/MS (Method 1). Extracted ion chromatograms are shown for each organ with standards (Figure S1).

**Candidate gene cloning**

The full-length sequences of the genes of interest were amplified from *C. pubescens* cDNA using the primers listed in Table S2. Genes annotated as medium-chain alcohol dehydrogenases (MDHs), esterases or O-methyl transferases (OMT) were cloned into either pOPINF or pOPINM vectors between BamHI and KpnI restrictions sites. Cytochrome P450 genes were cloned into pESC-leu2d::AaCPR vector suitable for yeast protein expression (Twist Bioscience). Note that pESC
vector encodes a copy of the Artemisia annua Cytochrome P450 Reductase necessary for P450 activity. The PCR products were purified from agarose gel and ligated into the suitable vector using the In-Fusion kit (Clontech Takara). Infusion reactions were transformed into competent E. coli Stellar cells (Clontech Takara). Recombinant colonies were selected on LB agar plates supplemented with carbenicillin (100 μg/mL). Positive clones were identified by colony PCR using sequencing primers designed for the specific vector used (Table S2). Plasmids were isolated from positive colonies grown overnight. Identities of the inserted sequences were confirmed by Sanger sequencing.

Protein expression and purification
Soluble medium-chain alcohol dehydrogenases, esterases and O-methyltransferases were expressed in E. coli soluBL21, while membrane-bound cytochromes P450 were expressed in S. cerevisiae PEP4KO.

E. coli soluBL21 expression and purification
E. coli soluBL21 were transformed with plasmids carrying the gene of interest by heat shock (ice, 20 minutes; 42 °C, 45 seconds). Transformed cells were selected by growing overnight at 37 °C on LB Agar plus carbenicillin 100 μg/mL. A single positive colony was grown in 10 mL S. cerevisiae -Out medium supplemented without Leucine 0.57% and purified at 30 °C for 24-48 hours. After protein induction microsomes were prepared by resuspending yeast cells into 30 mL TEK Buffer (50 mM Tris-HCl; 1 mM EDTA; 0.1 M KCl pH 7.4) and incubated for 5 minutes at room temperature. Cells were pelleted (4000 g; 10 minutes; 4 °C) and resuspended in 20 mL TES-B buffer (50 mM Tris-HCl; 1 mM EDTA; 0.6 M sorbitol pH 7.4). Cells were lysed using cell disruptor (30 KPa). Lysate was centrifuged at 110000 g for 20 minutes at 4 °C to precipitate intact cells, organelles and membranes. The supernatant was centrifuged in an ultra-centrifuge at 100000 g for 1 hour at 4 °C. The

S. cerevisiae expression and microsomes preparation
Yeast S. cerevisiae PEP4KO was transformed with pESC vector carrying the gene of interest, using the LiAc/SS-DNA/PEG protocol. Yeast was inoculated in 10 mL YPAD medium (yeast extract 1%; peptone 2%; glucose 2%; adenine sulfate dihydrate 40 mg/L) and incubated at 30 °C shaking overnight. The next day, the 10 mL culture was diluted 1:10 in 100 mL YPAD and incubated at the same conditions for 4-5 hours. After incubation, cells were pelleted by centrifugation (top speed, 5 minutes) and washed twice with sterile water. Cells were resuspended in transformation mix (for each transformation: 120 μL 50% PEG; 18 μL 1 M LiAc; 25 μL 2 mg/mL boiled carrier salmon sperm DNA) and aliquoted in 1.5 mL tubes. For each transformation 100-500 ng of plasmid DNA was added and mixed by pipetting. Transformation tubes were incubated at 42 °C in water bath for 30-40 minutes. After incubation, tubes were placed on ice for 1-3 minutes, then cells were pelleted and supernatant carefully removed. The cell pellet was resuspended in 150 μL sterile water and plated on Synthetic Complete SC-Leu Agar (Difco Yeast Nitrogen base without amino acids 0.335%; Sigma Yeast Synthetic Drop-Out medium supplemented without Leucine 0.196%; agar 2%; mono + dibasic sodium phosphate pH 7.4 5%) with addition of glucose 2%. Positive colonies appeared after 3-5 days of incubation at 30 °C.

A single positive colony was grown in 10 mL SC-Leu + 2% glucose at 30 °C overnight. The next day P450 expression was induced by inoculating all 10 mL into 100 mL of SC-Leu + 2% galactose and incubated at 30 °C for 24-48 hours. After protein induction microsomes were prepared by resuspending yeast cells into 30 mL TEK Buffer (50 mM Tris-HCl; 1 mM EDTA; 0.1 M KCl pH 7.4) and incubated for 5 minutes at room temperature. Cells were pelleted (4000 g; 10 minutes; 4 °C) and resuspended in 20 mL TES-B buffer (50 mM Tris-HCl; 1 mM EDTA; 0.6 M sorbitol pH 7.4). Cells were lysed using cell disruptor (30 KPa). Lysate was centrifuged at 110000 g for 20 minutes at 4 °C to precipitate intact cells, organelles and membranes. The supernatant was centrifuged in an ultra-centrifuge at 100000 g for 1 hour at 4 °C. The
resulting membrane pellet was resuspended in 150-300 µL of TEG buffer (50 mM Tris-HCl; 1 mM EDTA; 20% glycerol; pH 7.4) and gently mixed by pipetting. Microsomes were aliquoted, snap-frozen and kept at -80 °C.

Enzymatic assays
Enzyme candidates were tested as purified proteins in case of soluble MDH, esterases and OMTs. Cytochromes P450s were used as microsomal preparations or, alternatively, were tested by directly culturing the appropriate yeast cultures with the substrate present in the media at 100 µM concentration. For negative control experiments, soluble protein samples were replaced with boiled protein. For membrane bound P450s, the controls consisted of microsomes prepared from yeast transformed with pESC-leu2d::AaCPR empty vector, or in case of direct substrate feeding, yeast transformed with pESC-leu2d::AaCPR empty vector. After incubation, the reactions were quenched by addition of 1 volume of methanol, filtered through 0.22-µm nylon Spin-X centrifuge filters (Corning) and analyzed by untargeted UPLC/MS.

MDH and esterase assays.
MDH enzymes were tested in the presence of strictosidine 12 and C. roseus strictosidine glucosidase (CrSGD) to generate the strictosidine aglycone 3 substrate. Strictosidine aglycone 3 is highly reactive and thus cannot be isolated for these assays. Reaction mixtures consisted of MDH (1 µM) and CrSGD (1 µM) in a total volume of 50 µL. HEPES pH 7.5 (50 mM); strictosidine 12 (100 µM); NADPH (100 µM). Reactions were incubated at 30 °C for 1 hour. After incubation, the reactions were quenched by addition of 1 volume of methanol, filtered through 0.22-µm nylon Spin-X centrifuge filters (Corning) and analyzed by untargeted UPLC/MS (Method 2).

Since the dihydrocorynantheine aldehyde 18 product could not be successfully isolated, the activity of the esterases were assayed in the presence of CrSGD, the appropriate MDH (CpDCS) and strictosidine 12, using the same conditions described above, with the addition of the esterase protein to a final concentration of 1 µM.

Cytochrome P450 assays
Yeast feeding assays
Transformed yeast was grown in 10 mL SC-Leu + 2% glucose media overnight. The following day, 100 µL of culture was aliquoted and cells pelleted. To the cell pellet, 100 µL of SC-Leu + 2% galactose + the substrate (final concentration of 100 µM) was added. Substrates tested were: cinchonine 6; cinchonidine 7; and the cinchoninone 16 - cinchonidone 17 mix. The inducing medium was adjusted to pH 8 with Tris-base. Cultures were incubated with shaking for 24-48 hours at 30 °C. After incubation cells were pelleted and the supernatant was passed through a SPE column (Waters). Samples were analyzed by untargeted UPLC/MS (Method 1).

In vitro microsome assays
Microsomes were tested with substrates cinchonidine 7; cinchonine 6; cinchoninone 16 in excess of NADPH (1 mM). A total of 10 µL of microsomes was used in a final volume of 100 µL. The reactions were carried in HEPES pH 7.5 50 mM and incubated at 30 °C overnight. The next day, one volume of methanol was added, and microsomes pelleted by centrifugation. The supernatant was analyzed by untargeted UPLC/MS (Method 1).

OMT enzyme assays
OMT enzymes were tested using as substrates 6'-hydroxycinchonine 24; 6'-hydroxycinchonidine 25; and 6'-hydroxychinoninone 4, which exist in an inseparable tautomeric equilibrium. Assays were performed in 50 µL volume of Tris-base pH 8.5 50 mM; substrate concentration varied between 50 and 100 µM; SAM (200 µM) and ascorbate (200 µM) were used as cofactors; and the enzymes were diluted to a final concentration of 1-5 µM. Negative controls consisted of boiled OMT in the reaction mixture. Reactions were incubated at 30 °C for 1 to 12 hours. After incubation, the reactions were quenched by addition of 1 volume of methanol, filtered through 0.22-µm nylon Spin-X centrifuge filters (Corning) and analyzed by untargeted UPLC/QTOF (Method 1) (Figures S3).

CpOMT1 conversion rate
The conversion rate for the CpOMT1, was measured. CpOMT1 (1 µM) was incubated with 6'-hydroxycinchoninone 4 (100 µM) or 6'-hydroxycinchonidine 25 (100 µM) in the presence of SAM (200 µM) and ascorbate (200 µM) in Tris-Base pH 8.5 (50 mM) at 30 °C for 12 hours. All reactions were performed in triplicate. After incubation, the reactions were quenched by addition of 1 volume of methanol, filtered through 0.22-µm nylon Spin-X centrifuge filters (Corning) and analyzed by untargeted UPLC/MS (Method 1) (Figure S3).
To estimate the end point conversion the samples were measured by targeted UPLC/MS. Calibration curves were calculated for all substrates (6’-hydroxycinchonidine 25 and 6’-hydroxychinchoninone 4) and products (quinine 1 and 6’-methoxycinchonidine 18) by measuring triplicates of serial dilutions ranging from 12 nM to 800 nM and plotting each compound concentration against the peak integrals (Figure S4). Peak area was calculated for the substrates and products of CpOMT1 reactions diluted to fall within the linear range and their concentration was calculated using the calibration plot equation. Conversion was calculated as percentage of end point product concentration.

**Dihydrocorynantheal purification**

Dihydrocorynantheal 2 was produced by enzymatic conversion of strictosidine 12 using purified CrSGD, CpDCS, and CpDCE enzymes. The reaction mix consisted of 1 mL strictosidine 12 (300 µM); HEPES pH 7.5 50 mM; NADPH 300 µM; and the three enzymes, each at 1 µM. The reaction was incubated at 30 °C for 1 hour. A total of 10 reactions was run in parallel. After incubation, the samples were concentrated by SPE columns (Waters) and injected on Agilent HPLC system 1260 Infinity II and fractionated by Agilent 1290 Infinity II system. A semipreparative column was used (Phenomenex; Kinex 5µm XB-C18 100 Å; 250 x 10.0 mm) and a linear gradient 10%-30% acetonitrile in formic acid 0.1% in 35 minutes. The compound of interest was detected by UV absorption at wavelengths: 240 nm; 254 nm; and 290 nm. All fractions containing dihydrocorynantheal 2 were combined and dried by rotavapor. The product was then collected in 2 mL methanol, transferred in a glass vial and dried under argon at room temperature. Approximately 1 mg of dihydrocorynantheal 2 was recovered, and then subjected to NMR analysis (Figures S5-S23, Table S3). The enzymatic product was also analyzed by high resolution untargeted UPLC/MS (Method 2) and its molecular formula calculated using the function SmartFormula of the Compass DataAnalysis software (Bruker Compass HyStar 5.1 v.5.1.8.1). Tolerance was set at 2 ppm and charge state to +1. The analysis showed measured m/z 297.1959 with an error of 0.7 ppm, resulting in a calculated sum formula of C_{19}H_{24}N_{2}O.

**NMR analysis**

NMR spectra for dihydrocorynantheal 2 were measured on a 700 MHz Bruker Advance III HD spectrometer (Bruker Biospin GmbH, Rheinstetten, Germany). MeCN-d3 was used as a solvent. NMR spectra were referenced to the residual solvent signals at δH 1.96 and δC 118.26 ppm. For spectrometer control and data processing Bruker TopSpin ver. 3.6.1 was used (Figures S5-S23, Table S3).

For quinine analogs synthetic standards, NMR spectra were measured on a 400 MHz Bruker Advance III HD spectrometer (Bruker Biospin GmbH, Rheinstetten, Germany). CDCl3 was used as a solvent. NMR spectra were referenced to the residual solvent signals at δH 7.26 and δC 77.0 ppm. For spectrometer control and data processing Bruker TopSpin ver. 3.6.1 was used (Figures S24-S27).
Synthesis of Quinine Analogs
Cinchoninone 16 and Cinchonidone 17

To a stirred solution of DMSO (19 µL, 0.267 mmol) in anhydrous DCM (1 mL) was added oxalyl chloride (9.2 µL, 0.1079 mmol) dropwise at -78 ºC. After 30 min, cinchonidine 7 (15 mg, 0.0514 mmol) in anhydrous DCM (1 mL) was added dropwise at -78 ºC and the resulting mixture was stirred for 1 h at the same temperature. Then Et3N (64 µL, 0.457 mmol) was added at -78 ºC and stirred for 30 min. The reaction was quenched by 2 mL brine extracted with DCM, dried over anhydrous Na2SO4 and concentrated in vacuum. The resulted residue was purified by column chromatography (DCM/MeOH = 20/1) to afford cinchonidone 17 and cinchoninone 16 (11 mg, 73%) as a mixture (ratio = 1:1.3). The spectroscopic data are in accordance with the literature values reported.6,7

6´-Hydroxycinchonidine 25

To a stirred solution of quinine 1 (20 mg, 0.0617 mmol) in anhydrous DMF (0.6 mL) was added sodium ethane sulfide (37 mg, 0.246 mmol) at room temperature. The resulting mixture was heated at 110 ºC for 6 hours. After cooling the reaction to room temperature, the reaction mixture was quenched with sat. NH4Cl (1 mL), extracted with EtOAc, dried over anhydrous Na2SO4 and concentrated in vacuum. The resulted residue was purified by column chromatography (DCM/MeOH = 10/1) to afford 6´-hydroxycinchonidine 25 (10 mg, 52%). The spectroscopic data are in accordance with the literature values reported.8

6´-Hydroxycinchonine 24
To a stirred solution of quinidine 5 (20 mg, 0.0617 mmol) in anhydrous DMF (0.6 mL) was added sodium ethane sulfide (37 mg, 0.246 mmol) at room temperature. The resulting mixture was heated at 110 °C for 6 hours. After cooling the reaction to room temperature, the reaction mixture was quenched with sat. NH₄Cl (1 mL), extracted with EtOAc, dried over anhydrous Na₂SO₄ and concentrated in vacuum. The resulted residue was purified by column chromatography (DCM/MeOH = 10/1) to afford 6′-hydroxycinchonine 24 (9 mg, 47%). The spectroscopic data are in accordance with the literature values reported.

6′-Methoxycinchonidone 26 and 6′-Methoxycinchoninone 23

![Diagram](image.png)

To a stirred solution of DMSO (38 µL, 0.534 mmol) in anhydrous DCM (2 mL) was added oxalyl chloride (18.4 µL, 0.216 mmol) dropwise at -78 °C. After 30 min, quinine 1 (34 mg, 0.103 mmol) in anhydrous DCM (2 mL) was added dropwise at -78 °C and the resulting mixture was stirred for 1 h at the same temperature. Then Et₃N (128 µL, 0.914 mmol) was added at -78 °C and stirred for 30 min. The reaction was quenched by 4 mL brine extracted with DCM, dried over anhydrous Na₂SO₄ and concentrated in vacuum. The resulted residue was purified by column chromatography (DCM/MeOH = 20/1) to afford a mixture of 6′-methoxycinchonidone 26 and 6′-methoxycinchoninone 23 (30 mg, 88%, ratio = 1:1.3). The spectroscopic data are in accordance with the literature values reported.

6′-Hydroxycinchoninone 4

![Diagram](image.png)

To a stirred solution of DMSO (19 µL, 0.267 mmol) in anhydrous DCM (1 mL) was added oxalyl chloride (9.2 µL, 0.1079 mmol) dropwise at -78 °C. After 30 min, quinine 1 (17 mg, 0.0514 mmol) in anhydrous DCM (1 mL) was added dropwise at -78 °C and the resulting mixture was stirred for 1 h at the same temperature. Then Et₃N (64 µL, 0.457 mmol) was added at -78 °C and stirred for 30 min. The reaction was quenched by 2 mL brine extracted with DCM, dried over anhydrous Na₂SO₄ and concentrated in vacuum. The resulted residue was used in next step directly. To a stirred solution of above residue in anhydrous DMF (0.5 mL) was added sodium ethane sulfide (28 mg, 0.189 mmol) at room temperature. The resulting mixture was heated at 110 °C for 6 hours. After cooling the reaction to room temperature, the reaction mixture was quenched with sat. NH₄Cl (1 mL), extracted with EtOAc, dried over anhydrous Na₂SO₄ and concentrated in vacuum. The resulted residue was purified by column chromatography (DCM/MeOH = 50/1 to 10/1) to afford a mixture of diastereomers (14 mg, 88%).

1H NMR (400 MHz, CDCl₃, 1.5:1 mixture of diastereomers, * denotes major diastereomer) δ 8.76 (s, 1H, H2′), 8.75 (s, 1.5H, H2′*), 7.91 (d, J = 2.7 Hz, 1.5H, H5′*), 7.90 (d, J = 9.4 Hz, 1H, H8′), 7.86 (d, J = 9.1 Hz, 1.5H, H8′*), 7.76 (d, J = 2.6 Hz, 1H, H5′), 7.55 (d, J = 4.6 Hz, 1H, H3′), 7.50 (d, J = 4.5 Hz, 1H, H3′*), 7.26 (dd, J = 9.1, 2.6 Hz, 1H, H7′), 7.21 (dd, J = 9.1, 2.6 Hz, 1.5H, H7′*), 5.95 (ddd, J = 17.3, 10.5, 7.0 Hz, 1H, H10), 5.81 (ddd, J = 17.4, 10.3, 7.2 Hz, 1.5H, H10*), 5.11-5.16 (m, 2H, H11), 5.07-4.99 (m, 3H, H11*), 4.57 (t, J = 9.6 Hz, 2H, H8′*), 4.47 (t, J = 9.1 Hz, 1H, H8), 3.34-3.21 (m, 2.5H, H2, H2′*), 3.20 – 3.0 (m, 6.5H, H2, H2′*, H6, H6′* ), 2.84-2.81 (m, 1H, H6), 2.47-2.31 (m, 2.5H, H3, H3′*),
2.12 – 2.07 (m, 1.5H, H7*), 2.01-1.91(m, 3.5H, H7, H4, H4*), 1.90 – 1.70 (m, 5.5H, H7, H7*, H5*), 1.63 – 1.48 (m, 2H, H5);

$^{13}$C NMR (101 MHz, CDCl3, 1.5:1 mixture of diastereomers, * denotes major diastereomer) δ 201.8 (C9), 200.9 (C9*), 157.6 (C6’)*, 157.4 (C6’), 146.0 (C2’), 145.8 (C2’)*, 144.7 (C4’)*, 144.6 (C4’), 140.8 (C10), 139.6 (C10’), 139.2 (C10)*, 138.4 (C10’)*, 131.3 (C8’), 131.2 (C8’)*, 126.0 (C9’)*, 125.8 (C9’), 122.8 (C7’), 122.7 (C7’)*, 120.2 (C3’)*, 119.9 (C3’), 115.7 (C11)*, 115.2 (C11), 106.9 (C5’)*, 106.6 (C5’), 62.5 (C8), 61.7 (C8)*, 54.7 (C2), 49.1 (C6)*, 48.3 (C2)*, 43.0 (C6), 39.3 (C3)*, 38.9 (C3), 27.7 (C4’)*, 27.2 (C4), 26.9 (C5), 26.2 (C5)*, 23.4 (C7)*, 23.3 (C7).
Supplementary Figures and Tables

**Figure S1:** Extracted-ion chromatograms of *C. pubescens* leaves (1<sup>st</sup>, 2<sup>nd</sup>, and 3<sup>rd</sup>); stem; and roots. Plant extracts were compared with purchased quinine and analogs standards.

**Figure S2:** Enzymatic reactions of geissoschizine synthase, polyneuridine aldehyde esterase, tabersonine-16-hydroxylase and 16-hydroxytabersonine O-methyltransferase, which were used to search for gene candidates in *Cinchona*. 
Figure S3: Mass spectra and MS/MS fragmentation of peak 18.
Figure S4: $^1$H NMR of dihydrocorynantheal 2 with water suppression (zgpr), transmitter on 2.25 ppm, full range, in MeCN-$d_3$.

Figure S5: $^1$H NMR of dihydrocorynantheal 2 with water suppression (zgpr), detail, aromatic range, in MeCN-$d_3$. 
Figure S6: $^1$H NMR of dihydrocorynantheal 2 with water suppression (zgpr), detail, aliphatic range. Intensity of H-16b/21b is attenuated, in MeCN-$d_3$.

Figure S7: $^1$H-$^1$H DQFCOSY of dihydrocorynantheal 2 with water suppression, magnitude mode processed, full range, in MeCN-$d_3$. 
Figure S8: $^1$H-$^1$H DQFCOSY of dihydrocorynantheal 2 with water suppression, magnitude mode processed, aromatic range, in MeCN-$d_3$.

Figure S9: $^1$H-$^1$H DQFCOSY of dihydrocorynantheal 2 with water suppression, magnitude mode processed, aliphatic range, in MeCN-$d_3$. 
Figure S10: $^1$H-$^{13}$C HSQC of dihydrocorynantheal 2, full range. Shaded areas mark impurities, in MeCN-$d_3$.

Figure S11: $^1$H-$^{13}$C HSQC of dihydrocorynantheal 2, aromatic range, in MeCN-$d_3$. 
Figure S12: $^1$H-$^{13}$C HSQC of dihydrocorynantheal 2, aliphatic range. Shaded areas mark impurities, in MeCN-$d_3$.

Figure S13: $^1$H-$^{13}$C HMBC of dihydrocorynantheal 2, full range, in MeCN-$d_3$.
Figure S14: $^1$H-$^{13}$C HMBC of dihydrocorynantheal 2, detail, shaded area marks impurities, in MeCN-$d_3$.

Figure S15: $^1$H-$^{13}$C HMBC of dihydrocorynantheal 2, detail, shaded area marks impurities, in MeCN-$d_3$. 
Figure S16: $^1$H-$^{13}$C HMBC of dihydrocorynantheal 2, detail, in MeCN-$d_3$.

Figure S17: $^1$H-$^{13}$C HMBC of dihydrocorynantheal 2, detail, shaded area marks impurities, in MeCN-$d_3$. 
Figure S18: $^1$H-$^{13}$C HMBC of dihydrocorynantheal 2, detail, aromatic range, in MeCN-$d_3$.

Figure S19: $^1$H-$^{13}$C HMBC of dihydrocorynantheal 2, detail, shaded area marks impurities, in MeCN-$d_3$. 
Figure S20: $^1$H-$^1$H SELTOCSY of dihydrocorynantheal 2, transmitter on H-3, 120 ms mixing time, in MeCN-$d_3$. 
Figure S21: $^1$H-$^1$H SELTOCSY of dihydrocorynantheal 2, transmitter on H-19b, 120 ms mixing time, in MeCN-$d_3$.

Figure S22: $^1$H-$^1$H SELTOCSY of dihydrocorynantheal 2, transmitter on H-6a, 120 ms mixing time, in MeCN-$d_3$. 
Figure S23: $^1$H–$^1$H ROESY of dihydrocorynantheal 2, with water suppression, spin lock 400 ms, in MeCN-$d_3$.

Figure S24: $^1$H–$^1$H ROESY of dihydrocorynantheal 2, with water suppression, detail, spin lock 400 ms, in MeCN-$d_3$. 
Figure S25: $^1$H-$^1$H ROESY of dihydrocorynantheal 2, with water suppression, detail, spin lock 400 ms, in MeCN-$d_3$. 
Figure S26: Structure of dihydrocorynantheal 2 optimized using Gaussian 16W (PM6, solvent MeCN). Important ROESY correlations are depicted in green. The assignment is based on definition of all alpha-oriented protons starting from H-3. The orientation of H-20 was deduced from the correlation H-21b→H-20. The configuration of position 6 was assigned from ROESY correlations to H-9 and H-5β.
Figure S28: $^1$H-NMR of 6′-hydroxycinchoninone 4, 400 MHz, CDCl$_3$, 298 K

Figure S29: $^{13}$C-NMR of 6′-hydroxycinchoninone 4, 101 MHz, CDCl$_3$, 298 K
Figure S30: $^1$H-$^1$H COSY of 6'-hydroxycinchoninone 4, 400 MHz, CDCl$_3$, 298 K

Figure S31: HSQC of 6'-hydroxycinchoninone 4, 400 MHz, CDCl$_3$, 298 K
Figure S32: TIC traces of competition assay between substrates 25 and 4 incubated with CpOMT1 for 12 hours. Notice that all ketone analogs are in an inseparable tautonomic equilibrium, as indicated by the two peaks in the chromatogram. * indicates an unrelated impurity.

Figure S33: calibration curves for substrates and products of CpOMT1.
### Table S1. Quantifier and qualifier m/z fragments used to calculate CpOMT1 product conversion

| Compound                        | Precursor ion m/z | Quantifier m/z [collision energy] | Qualifier m/z [collision energy] |
|---------------------------------|-------------------|-----------------------------------|-----------------------------------|
| Quinine                         | 163.1             | 188.9 [15.0 V]                    |                                   |
| 6'-methoxycinchoninone          | 162.1             | 159.0 [19.0 V]                    | 214.0 [13.0 V]; 67.2 [16.0 V]; 115.0 [13.0 V] |
| 6'-hydroxycinchonidine          | 156.1             | 174.9 [16.0 V]                    | 145.9 [26.0 V]; 202.9 [12.0 V]; 67.2 [15.0 V] |
| 6'-hydroxycinchoninone          | 155.1             | 145.0 [22.0 V]                    | 200.9 [12.0 V]; 67.2 [16.0 V]; 108.1 [13.0 V] |

### Table S2. Primer list

| Primers                         | Primer sequence                                      | Gene function |
|---------------------------------|------------------------------------------------------|---------------|
| pOPINF seq fw                   | CGGGACCTTTTAATTCAACCCAAAC                            |               |
| pOPINF seq re                   | CACCACCTTCTGATAGGCAG                                  | Sequencing    |
| pESC seq fw                     | GGTGGAATGCCATGTAATATG                                 | and colony    |
| pESC seq re                     | GGCAAGGTAGACAGCCGACAC                                 | PCR           |
| pOPINM seq fw                   | GAAATCATGCCCACATC                                     |               |
| pOPINM seq re                   | TAGCCACAAGTCAAGATGCT                                  |               |
| pOPINF-Cp2794.con4 fw           | AAGTTCTGTTCAGGGCCCGGCAAAACACCAACACAGACAA          | MDHs          |
| pOPINF-Cp2794.con4 re           | ATGGTCTAGAAGACTTTAAGCTTATATGATTTACAAATATC            |               |
| pOPINF-Cp39479 fw               | AAGTTCTGTTCAGGGCCCGGCTTACACAGAAGTGGA                |               |
| pOPINF-Cp39479 re               | ATGGTCTAGAAGACTTTAAGCTTATATGATTTACAAATATC            |               |
| pOPINF-Cp1238 fw                | AAGTTCTGTTCAGGGCCCGGCTTACACAGAAGTGGA                |               |
| pOPINF-Cp1238 re                | ATGGTCTAGAAGACTTTAAGCTTATATGATTTACAAATATC            |               |
| pOPINF-Cp13924 fw               | AAGTTCTGTTCAGGGCCCGGCTTACACAGAAGTGGA                |               |
| pOPINF-Cp13924 re               | ATGGTCTAGAAGACTTTAAGCTTATATGATTTACAAATATC            |               |
| pOPINF-Cp10715 fw               | ATGGTCTAGAAGACTTTAAGCTTATATGATTTACAAATATC            |               |
| pOPINF-Cp10715 re               | ATGGTCTAGAAGACTTTAAGCTTATATGATTTACAAATATC            |               |
| pOPINF-Cp14456.con2 fw          | ATGGTCTAGAAGACTTTAAGCTTATATGATTTACAAATATC            |               |
| pOPINF-Cp14456.con2 re          | ATGGTCTAGAAGACTTTAAGCTTATATGATTTACAAATATC            |               |
| pOPINF-Cp15915 fw               | ATGGTCTAGAAGACTTTAAGCTTATATGATTTACAAATATC            |               |
| pOPINF-Cp15915 re               | ATGGTCTAGAAGACTTTAAGCTTATATGATTTACAAATATC            |               |
| pOPINF-Cp640 fw                  | ATGGTCTAGAAGACTTTAAGCTTATATGATTTACAAATATC            |               |
| pOPINF-Cp640 re                  | ATGGTCTAGAAGACTTTAAGCTTATATGATTTACAAATATC            |               |
| pOPINF-Cp1494 fw                | ATGGTCTAGAAGACTTTAAGCTTATATGATTTACAAATATC            |               |
| pOPINF-Cp1494 re                | ATGGTCTAGAAGACTTTAAGCTTATATGATTTACAAATATC            |               |
| pOPINF-Cp1348 fw                 | ATGGTCTAGAAGACTTTAAGCTTATATGATTTACAAATATC            |               |
| pOPINF-Cp1348 re                 | ATGGTCTAGAAGACTTTAAGCTTATATGATTTACAAATATC            |               |
| pOPINF-Cp19597 fw | AAGTTCTGTTCAGGGCCCGCCAGATAAAATGAAAATTTTTG |
|-------------------|-----------------------------------------------|
| pOPINF-Cp19597 re | ATGGTCTAGAAGCTTTATTTAATTATGTGTAGCATG       |
| pOPINF-Cp394 fw   | AAGTTCTGTTCAGGGCCCGGCTGTCGAGTCTCAAATTTT    |
| pOPINF-Cp394 re   | ATGGTCTAGAAGCTTTAGTTATGAATGCAGCAAGAAGT     |
| pOPINF-Cp12411 fw | AAGTTCTGTTCAGGGCCCGGCTACAATTAGAGAGTACCT   |
| pOPINF-Cp12411 re | ATGGTCTAGAAGCTTTAGACCTCTGCGTCCAAC          |
| pOPINF-Cp6072 fw  | AAGTTCTGTTCAGGGCCCGGCTGTCGAGTCTCAAATTTT    |
| pOPINF-Cp6072 re  | ATGGTCTAGAAGCTTTAGTTATGAATGCAGCAAGAAGT     |
| pOPINF-Cp5024 fw  | AAGTTCTGTTCAGGGCCCGGCTACAATTAGAGAGTACCT   |
| pOPINF-Cp5024 re  | ATGGTCTAGAAGCTTTAGACCTCTGCGTCCAAC          |
| pOPINF-CpDCS fw   | AAGTTCTGTTCAGGGCCCGGCTGTCGAGTCTCAAATTTT    |
| pOPINF-CpDCS re   | ATGGTCTAGAAGCTTTAGTTATGAATGCAGCAAGAAGT     |
| pESC-Cp2088.con3 fw | ACCCTCACTAAAGGGCGGCCGCAACCATGAAAATGGAATTTTCCTTC |
| pESC-Cp2088.con3 re | GTCATCCTTGTAATCCATCGATACATTAGGTAGACTTGCAACAAG |
| pESC-Cp10558.con5 fw | ACCCTCACTAAAGGGCGGCCGCAACCATGCTTCTTTCCAGGTAG |
| pESC-Cp10558.con5 re | GTCATCCTTGTAATCCATCGATACATTAGGTAGACTTGCAACAAG |
| pESC-Cp1125.con6 fw | ACCCTCACTAAAGGGCGGCCGCAACCATGAAAATGGAATTTTCCTTC |
| pESC-Cp1125.con6 re | GTCATCCTTGTAATCCATCGATACATTAGGTAGACTTGCAACAAG |
| pESC-Cp4378 fw   | ACCCTCACTAAAGGGCGGCCGCAACCATGAAAATGGAATTTTCCTTC |
| pESC-Cp4378 re   | GTCATCCTTGTAATCCATCGATACATTAGGTAGACTTGCAACAAG |
| pESC-Cp27708 fw  | ACCCTCACTAAAGGGCGGCCGCAACCATGAAAATGGAATTTTCCTTC |
| pESC-Cp27708 re  | GTCATCCTTGTAATCCATCGATACATTAGGTAGACTTGCAACAAG |
| pESC-Cp8105.con1 fw | ACCCTCACTAAAGGGCGGCCGCAACCATGAAAATGGAATTTTCCTTC |
| pESC-Cp8105.con1 re | GTCATCCTTGTAATCCATCGATACATTAGGTAGACTTGCAACAAG |
| pESC-Cp12022.con2 fw | ACCCTCACTAAAGGGCGGCCGCAACCATGAAAATGGAATTTTCCTTC |
| pESC-Cp12022.con2 re | GTCATCCTTGTAATCCATCGATACATTAGGTAGACTTGCAACAAG |
| pESC-Cp24354 fw  | ACCCTCACTAAAGGGCGGCCGCAACCATGAAAATGGAATTTTCCTTC |
| pESC-Cp24354 re  | GTCATCCTTGTAATCCATCGATACATTAGGTAGACTTGCAACAAG |
| pESC-Cp28986 fw  | ACCCTCACTAAAGGGCGGCCGCAACCATGAAAATGGAATTTTCCTTC |
| pESC-Cp28986 re  | GTCATCCTTGTAATCCATCGATACATTAGGTAGACTTGCAACAAG |
| pESC-Cp620.con9 fw | ACCCTCACTAAAGGGCGGCCGCAACCATGAAAATGGAATTTTCCTTC |
| pESC-Cp620.con9 re | GTCATCCTTGTAATCCATCGATACATTAGGTAGACTTGCAACAAG |
| pESC-Cp7234 fw   | ACCCTCACTAAAGGGCGGCCGCAACCATGAAAATGGAATTTTCCTTC |
| pESC-Cp7234 re   | GTCATCCTTGTAATCCATCGATACATTAGGTAGACTTGCAACAAG |
| pESC-Cp16649 fw  | ACCCTCACTAAAGGGCGGCCGCAACCATGAAAATGGAATTTTCCTTC |
| pESC-Cp16649 re  | GTCATCCTTGTAATCCATCGATACATTAGGTAGACTTGCAACAAG |
| pESC-Cp7253.con4 fw | ACCCTCACTAAAGGGCGGCCGCAACCATGAAAATGGAATTTTCCTTC |
| pESC-Cp7253.con4 re | GTCATCCTTGTAATCCATCGATACATTAGGTAGACTTGCAACAAG |
| pESC-Cp8609 fw   | ACCCTCACTAAAGGGCGGCCGCAACCATGAAAATGGAATTTTCCTTC |
| pESC-Cp8609 re   | GTCATCCTTGTAATCCATCGATACATTAGGTAGACTTGCAACAAG |
| pESC-Cp3825.con6 fw | ACCCTCACTAAAGGGCGGCCGCAACCATGAAAATGGAATTTTCCTTC |
| pESC-Cp3825.con6 re | GTCATCCTTGTAATCCATCGATACATTAGGTAGACTTGCAACAAG |

**Cytochromes P450**
| pESC-Cp3825.con6 re | GTCATCCTTGTAATCCATCGATACGTAGAGTGGACAAAGCAAAC |
|--------------------|-----------------------------------------------|
| pESC-Cp12767 fw    | ACCCTCACTAAGGGGCCGCGCAACCATGATGTCTGATCTTTAAACA |
| pESC-Cp12767 re    | GTCACTCCTTGTAATCCATCGATACGTAGAGTGGACAAAGCAA |
| pESC-Cp35516 fw    | ACCCTCACTAAGGGGCCGCGCAACCATGATGTCTGATCTTTAAACA |
| pESC-Cp35516 re    | GTCACTCCTTGTAATCCATCGATACGTAGAGTGGACAAAGCAA |
| pESC-Cp1963.con4 fw| ACCCTCACTAAGGGGCCGCGCAACCATGATGTCTGATCTTTAAACA |
| pESC-Cp1963.con4 re| GTCACTCCTTGTAATCCATCGATACGTAGAGTGGACAAAGCAA |
| pESC-Cp17862 fw    | ACCCTCACTAAGGGGCCGCGCAACCATGATGTCTGATCTTTAAACA |
| pESC-Cp17862 re    | GTCACTCCTTGTAATCCATCGATACGTAGAGTGGACAAAGCAA |
| pESC-Cp2392.con6 fw| ACCCTCACTAAGGGGCCGCGCAACCATGATGTCTGATCTTTAAACA |
| pESC-Cp2392.con6 re| GTCACTCCTTGTAATCCATCGATACGTAGAGTGGACAAAGCAA |
| pOPINF-Cp23298 fw  | AAGTTCTGTTTCAGGGCCCGGATCCAGCAATTCCAA |
| pOPINF-Cp23298 re  | ATGGTCTAGAAAGCTTTAGATATATTTATCAGTTATTTCTTG |
| pOPINF-Cp10039 fw  | AAGTTCTGTTTCAGGGCCCGGGAAGGTGAGAAGCAGCA |
| pOPINF-Cp10039 re  | ATGGTCTAGAAAGCTTTAATTAAATGGAACCAAAGTC |
| pOPINF-Cp23301 fw  | AAGTTCTGTTTCAGGGCCCGTTTTGCGTTACTTACACTTCA |
| pOPINF-Cp23301 re  | ATGGTCTAGAAAGCTTTAGATGTGTTCATCAACTATCTCT |
| pOPINF-Cp40444 fw  | AAGTTCTGTTTCAGGGCCGGAATGGTGAAGCAGAC |
| pOPINF-Cp40444 re  | ATGGTCTAGAAAGCTTTAATTAGGAGGGTTTTGATCC |
| pOPINF-Cp7988 fw   | AAGTTCTGTTTCAGGGCCCGGATATTTCAAGTCAATTGGTCA |
| pOPINF-Cp7988 re   | ATGGTCTAGAAAGCTTTAATTACATCTCTCAGCAATTTC |
| pOPINF-CpDCE fw    | AAGTTCTGTTTCAGGGCCGGAATGGTGAAGCAGAC |
| pOPINF-CpDCE re    | ATGGTCTAGAAAGCTTTAATTACATCTCTCAGCAATTTC |
| pOPINF-Cp10350.con2 fw | AAGTTCTGTTTCAGGGCCGGAATGGTGAAGCAGAC |
| pOPINF-Cp10350.con2 re | ATGGTCTAGAAAGCTTTAATTACATCTCTCAGCAATTTC |
| pOPINF-Cp3175.con4 fw | AAGTTCTGTTTCAGGGCCGGAATGGTGAAGCAGAC |
| pOPINF-Cp3175.con4 re | ATGGTCTAGAAAGCTTTAATTACATCTCTCAGCAATTTC |
| pOPINF-Cp11359 fw  | AAGTTCTGTTTCAGGGCCGGAATGGTGAAGCAGAC |
| pOPINF-Cp11359 re  | ATGGTCTAGAAAGCTTTAATTACATCTCTCAGCAATTTC |
| pOPINF-Cp12638 fw  | AAGTTCTGTTTCAGGGCCGGAATGGTGAAGCAGAC |
| pOPINF-Cp12638 re  | ATGGTCTAGAAAGCTTTAATTACATCTCTCAGCAATTTC |
| pOPINF-Cp6036.con1 fw | AAGTTCTGTTTCAGGGCCGGAATGGTGAAGCAGAC |
| pOPINF-Cp6036.con1 re | ATGGTCTAGAAAGCTTTAATTACATCTCTCAGCAATTTC |
| pOPINF-Cp11992.con4 fw | AAGTTCTGTTTCAGGGCCGGAATGGTGAAGCAGAC |
| pOPINF-Cp11992.con4 re | ATGGTCTAGAAAGCTTTAATTACATCTCTCAGCAATTTC |
| pOPINF-CpOMT1 fw   | AAGTTCTGTTTCAGGGCCGGAATGGTGAAGCAGAC |
| pOPINF-CpOMT1 re   | ATGGTCTAGAAAGCTTTAATTACATCTCTCAGCAATTTC |

**Esterases**

**OMTs**
Table S3. Tabulated NMR values of dihydrocorynantheal 2

| pos. | \( \delta_H \) | mult. | \( J_{HH} \) | \( \delta_C \) |
|------|----------------|-------|--------------|--------------|
| 1    | 9.06           | s     |              |              |
| 2    | -              | -     |              | 134.3        |
| 3    | 3.46           | bd    | 12.0         | 59.9         |
| 4    | -              | -     |              |              |
| 5a   | 3.18           | dd    | 5.6/10.0     | 52.9         |
| 5b   | 2.69           | dd    | 4.0/10.0     | 52.9         |
| 6a   | 2.92           | m     | -            | 21.0         |
| 6b   | 2.72           | d     | 13.5         | 21.0         |
| 7    | -              | -     |              | 107.3        |
| 8    | -              | -     |              | 127.1        |
| 9    | 7.41           | d     | 8.0          | 117.9        |
| 10   | 7.02           | ddd   | 8.0/7.0/1.0  | 119.0        |
| 11   | 7.08           | ddd   | 8.0/7.0/1.0  | 121.3        |
| 12   | 7.30           | d     | 8.0          | 111.2        |
| 13   | -              | -     |              | 136.6        |
| 14a  | 2.34           | ddd   | 3.0/3.2/12.0 | 35.5         |
| 14b  | 1.34           | q     | 12.0         | 35.5         |
| 15   | 1.96           | m     | -            | 35.0         |
| 16a  | 2.74           | dd    | 3.1/16.0     | 47.0         |
| 16b  | 2.26           | m     | -            | 47.0         |
| 17   | 9.78           | bs    | -            | 203.5        |
| 18   | 0.92           | t     | 7.5          | 10.3         |
| 19a  | 1.60           | m     | -            | 23.3         |
| 19b  | 1.17           | m     | -            | 23.3         |
| 20   | 1.53           | m     | -            | 41.3         |
| 21a  | 3.19           | dd    | 4.1/11.4     | 59.5         |
| 21b  | 2.27           | dd    | 11.4/11.4    | 59.5         |
References

(1) Carmo, H. M.; Braz-Filho, R.; Vieira, I. J. C.; A novel alkaloid from aspidosperma pyricollum (Apocynaceae) and complete $^1$H and $^{13}$C chemical shift assignments. Helv Chim Acta 2015, 98, 1381-1386.

(2) Lichman, B. R.; Godden, G. T.; Hamilton, J. P.; Palmer, L.; Kamileen, M. O.; Zhao, D.; Vaillancourt, B.; Wood, J. C.; Sun, M.; Kinser, T. J.; Henry, L. K.; Rodriguez-Lopez, C.; Dudareva, N.; Soltis, D. E.; Soltis, P. S.; Buell, C. R.; O'Connor, S. E. The evolutionary origins of the cat attractant nepetalactone in catnip. Sci Adv. 2020, 6, eaba0721.

(3) Maisel, L; Fonseca, B.; Gonzales, S.; Baeza-Yates, R.; Cambiazo, V.; Campos, R.; Gonzales, M.; Orellana, A.; Retamales, J.; Silva, H. A rapid and efficient method for purifying high quality total RNA from peaches Prunus persica for functional genomics analyses. Biol. Res. 2005, 38, 1, 83-88.

(4) Berrow, N. S.; Alderton, D.; Sainsbury, S.; Nettleship, J.; Assenberg, R.; Rahman, N.; Stuart, D. I.; Owens, R. J. A versatile ligation-independent cloning method suitable for high throughput expression screening applications. Nucleic Acids Res. 2007, 35, e45.

(5) Gietz, R. D.; Schiestl, R. H. High-efficiency yeast transformation using the LiAc/SS carrier DNA/PEG method. Nature Protocols 2007, 2, 31-34.

(6) Leroux, S.; Larquetoux, L.; Nicolas, M.; Doris, E. Asymmetric Synthesis of (+)-Mequitazine from Quinine. Org. Lett. 2011, 13, 3549–3551.

(7) Boratyn’ski, P. J.; Turowska-Tyrk, I.; Skarzewski, J. Synthetic approaches to 9-arylated Cinchona alkaloids: stereoselective addition of Grignard reagents to cinchonanones and hydroxylation of 9-phenylcinchonanes. Tetrahedron: Asymmetry 2012, 23, 876–883.

(8) Li, H.; Wang, Y.; Tang, L.; Deng, L. Highly Enantioselective Conjugate Addition of Malonate and β-Ketoester to Nitroalkenes: Asymmetric C−C Bond Formation with New Bifunctional Organic Catalysts Based on Cinchona Alkaloids. J. Am. Chem. Soc. 2004, 126, 32, 9906–9907.

(9) Smith, A. C.; Williams, R. M. Rabe Rest in Peace: Confirmation of the Rabe–Kindler Conversion of d-Quinotoxine Into Quinine: Experimental Affirmation of the Woodward–Doering Formal Total Synthesis of Quinine. Angew. Chem. Intl. Ed. 2008, 47, 1736 –1740.
The Royal Botanic Gardens, Kew ("Kew") is committed to the letter and spirit of the Convention on Biological Diversity ("CBD") and expects its partners to act in a manner consistent with the CBD. This agreement is designed to promote scientific research and exchange, whilst recognising the terms on which Kew acquired the plant or fungal material and the important role played by ex situ collections in the implementation of the CBD. Kew reserves the right not to supply any plant or fungal material if such supply would be contrary to any terms attached to the material and/or to the CBD.

Kew will supply the material listed on the reverse of this agreement ("Material") subject to the following terms and conditions:

1. The recipient may only use the Material, its progeny or derivatives for the common good in scientific research, education, conservation and the development of botanical gardens;

2. The recipient shall **not sell, distribute or use for profit or any other commercial application** the Material, its progeny or derivatives;

3. The recipient shall **share fairly and equitably** the benefits arising from their use of the Material, its progeny or derivatives in accordance with the CBD. You will find a non-exhaustive list of non-monetary and monetary benefits at Appendix II to the Bonn Guidelines: [www.biodiv.org/programmes/socio-eco/benefits/bonn.asp](http://www.biodiv.org/programmes/socio-eco/benefits/bonn.asp);

4. The recipient shall **acknowledge** Kew, as supplier, in all written or electronic reports and publications resulting from their use of the Material, its progeny and derivatives and shall **lodge a copy** of all such publications and reports with Kew;

5. The recipient shall take **all appropriate and necessary measures** to import the Material in accordance with relevant laws and regulations and to contain the Material, its progeny or derivatives so as to prevent the release of invasive alien species;

6. The recipient may only **transfer** the Material, its progeny or derivatives to a bona fide third party such as a botanical garden, university or scientific institution **for non-commercial use** in the areas of scientific research, education, conservation and the development of botanical gardens. All transfers shall be subject to the terms and conditions of this agreement. The recipient shall **notify Kew** of all such transfers and, on request, shall provide Kew with copies of the relevant material transfer agreement;

7. The recipient shall maintain **retrievable records** linking the Material to these terms of acquisition and to any accompanying Data provided by Kew;

8. Unless otherwise indicated, **copyright** in all information or data ("Data") supplied with the Material is owned by Kew or Kew’s licensors. You may use this Data on condition that it is used solely for scholarly, education or research purposes; that it is not used for commercial purposes; and that you always acknowledge the source of the Data with the words “With the permission of the Board of Trustees of the Royal Botanic Gardens, Kew”;

9. Kew makes **no representation or warranty** of any kind, either express or implied, as to the identity, safety, merchantability or fitness for any particular purpose of the Material, its progeny or derivatives, or as to the accuracy or reliability of any Data supplied. The recipient will indemnify Kew from any and all liability arising from the Material, its progeny or derivatives and/or the Data and from their use or transfer, including any ecological damage. This agreement is governed by and shall be construed in accordance with English law;

10. The recipient will contact Kew to request **prior permission** from Kew or, where appropriate, from the provider of the Material to Kew, for any activities not covered under the terms of this agreement.

---

I agree to comply with the conditions above: 20061109 - 20061110

| Signed: | Date: dd/mm/yy | Name and Position: | Organisation and Department: |
|---------|----------------|-------------------|-----------------------------|
| Gallonay | 15/08/06 | Louise Gallonay | Royal Botanic Garden Edinburgh |
| Address: | E-mail: l-gallonay@rbge.org.uk | 20A Inverleith Row | Tel. Number: 0131-248-2919 |

Please return a signed copy to: Nic.R..T., C.G.T., Royal Botanic Gardens, Kew, Richmond, Surrey TW9 3AE, United Kingdom.

Kew Staff Signature: Name/Position/Date: dd/mm/yy:

---

1 For the purposes of this agreement, commercial application shall mean: applying for, obtaining or transferring intellectual property rights or other tangible or intangible rights by sale or licence or in any other manner, commencement of product development, conducting market research, seeking pre-market approval; and/or the sale of any resulting product.
1. In response to the Convention on Biological Diversity, the Royal Botanic Garden Edinburgh supplies living plant material, preserved material, seed, DNA and pollen samples on condition that:

a) The material is used for the common good in areas of Research, Education, Conservation and the development of Botanic Gardens.

b) Access to material from RBGE's collections is for non-commercial use only. If the recipient seeks to commercialise the genetic material, its products or resources derived from it, then written permission must be sought from the RBGE. Such commercialism will be subject to the conditions of a separate agreement.

c) The genetic material, its products or resources deriving from it are not passed on to a third party for commercialisation without written permission from the country of origin and the Royal Botanic Garden Edinburgh in accordance with the Convention on Biological Diversity.

2. It is a condition of supply that any publication resulting from the use of plant material should acknowledge the Royal Botanic Garden Edinburgh as supplier or, under certain circumstances, be published in collaboration with staff from RBGE. A copy of any publication, report or data gained from the material MUST be lodged with the Royal Botanic Garden Edinburgh.

3. A voucher specimen will be taken for material used for scientific purposes. This specimen will be kept at the RBGE and will be released on a loan basis. The cultivated collector and number must be referred to when requesting the voucher specimen and citing the material, not the accession number or the wild collector and number.

5. An aliquot from each DNA sampling will be returned to the RBGE.

6. Nagoya Protocol Compliance: from 12th October 2014 plant material requested from RBGE may be subject to Prior Informed Consent from the country of origin. Any permissions and conditions of use will be advised before release and if there are any restrictions it will not be made available. RBGE reserves the right to refuse, without explanation if necessary, to supply genetic resources to a recipient.

7. The Royal Botanic Garden Edinburgh cannot guarantee the material as verified.

Please return this form to:
Peter Brownless,
Royal Botanic Garden Edinburgh
20A Inverleith Row, Edinburgh, EH3 5LR
Scotland, UK.
Fax: +44 (0)131 248 2901
Email attachment as a JPEG or Pdf to p.brownless@rbge.org.uk

For official use
Internal contact: __________________
Desiderata number: __________________
Psource number: __________________
CBD DS# __________________
Other __________________

I agree to comply with the conditions above.

| NAME       | Sarah O'Connor | Position of Representative: | Project leader/Professor |
|------------|----------------|-----------------------------|-------------------------|
| Organisation: | John Innes Centre |                           |                         |
| Department: | Biological Chemistry |                        |                         |
| Address:    | Norwich research park |                       |                         |
| Post/Zip code: | NR4 7UH |                      |                         |
| Tel. Number: | 01603 450334 |                    |                         |
| Email:      | Sarah.oconnor@jic.ac.uk |                  |                         |
| Signed:     | __________________ |                    |                         |

Please retain a copy of this form for your own records
Compliance with the terms of the Nagoya protocol

The Nagoya Protocol on access to genetic resources and the fair and equitable sharing of benefits arising from their utilization to the Convention on Biological Diversity is a supplementary to Convention on Biological Diversity (CBD) and was adopted by European legislation on 13th October 2014.

The Nagoya Protocol provides a transparent legal framework for the implementation of fair and equitable sharing of benefits arising out of the utilization of genetic resources. The Protocol applies to all genetic resources covered by the CBD, the traditional knowledge associated with those resources and the benefits arising from the utilization of those resources.

The Protocol sets out three types of obligations:

Access obligations include providing fair and non-arbitrary procedures for access, establishing clear procedures for prior informed consent and creating conditions to promote and encourage research.

Benefit-sharing obligations include measures to provide for the fair and equitable sharing of benefits arising from the utilisation of genetic resources. Utilization includes research and development on the genetic or biochemical composition of genetic resources, as well as subsequent applications and commercialisation.

Compliance obligations include ensuring genetic resources have been accessed in accordance with prior informed consent and monitoring the utilization of genetic resources.

Oxford University Herbaria, Botanic Garden and Harcourt Arboretum (OHBGHA) intend to honour the letter and spirit of the Nagoya Protocol:

1. All material accessed to collections after 13th October 2014 will require evidence it has been collected legally, with the consent of the originating country. Copies of all evidence will be associated with each accession record.

2. All material accessed after 13th October 2014 will be tagged as such in electronic databases and its use restricted until appropriate agreements have been signed.

3. Ethnobotanical data, associated with material accessed under the Nagoya Protocol, via web-based databases will be restricted to registered database users who have signed appropriate agreements.

4. All use of material in OHBGHA under the Nagoya Protocol will be recorded. Agreement to the terms of the Protocol will be obtained by signing the form ‘Collections Access Agreement for University of Oxford Herbaria, Botanic Garden & Harcourt Arboretum’.

For additional information regarding the Nagoya Protocol: CBD (2011) Nagoya Protocol on Access to Genetic Resources and the Fair and Equitable Sharing of Benefits Arising from their Utilization to the Convention on Biological Diversity. Secretariat of the Convention on Biological Diversity; Darwin Initiative (2014) Learning note: the Nagoya Protocol. Department for Environment, Food & Rural Affairs; Greiber, T. et al. (2012) An explanatory guide to the Nagoya Protocol on access and benefit-sharing. IUCN Environmental Policy and Law Paper No. 83.